

Prior Authorization Request Form Immunomodulator Agents

Standard Urgent

Reconsideration/Appeal

Patient Information

Patient Name: _____ DOB (mm/dd/yyyy): _____ Gender: _____
 Address: _____ City: _____ State & Zip: _____
 Cardholder ID: _____ Group #: _____ Relationship Code: _____
 Phone Number: _____ Email address: _____

Prescriber Information

Prescriber Name: _____ Specialty: _____ NPI: _____
 Address: _____ City: _____ State & Zip: _____
 Office Contact: _____ Phone Number: _____ Fax Number: _____

Medication Information

Drug Name: _____ Strength: _____ Quantity: _____
 Directions: _____ Day Supply: _____
 Indicate Request Type: New Start Renewal Therapy Start Date (if applicable): _____
 Diagnosis: _____ ICD 10 Code: _____

Prior Authorization Request Information

****Supporting documentation (i.e., chart notes, labs, etc.) must be attached to avoid processing delays****

Please be aware that our preferred Humira biosimilars are adalimumab-aacf, adalimumab-aaty, adalimumab-fkjp, Hadlima, Simlandi, & Yusimry

For all requests:

- | | |
|---|--|
| 1. Does the patient have any FDA contraindications to the requested agent? | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 2. Is the requested agent being prescribed by or in consultation with an appropriate specialist? | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 3. Will the requested agent be used in combination with any other biologic DMARD or targeted synthetic DMARD? If yes, please explain: _____ | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 4. Has the patient been tested negative for TB? Please provide documentation of results. | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 5. If positive for latent TB, has the patient completed treatment (or is receiving treatment)? | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 6. Does the provider attest that the patient does not have an active infection (including tuberculosis and hepatitis B virus (HBV), and the patient has been counseled on next steps if they were to develop an active infection? | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 7. Will the patient receive any live vaccines while on therapy? | <input type="checkbox"/> Yes <input type="checkbox"/> No |

Please continue to the next page.

Patient Name:	DOB:
---------------	------

For Rheumatoid Arthritis Requests:

1. Does the patient have moderate-to-severe rheumatoid arthritis? Yes No

2. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of ONE conventional systemic DMARD therapy (i.e., azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate, or sulfasalazine)? Yes No

Drug Name/Strength:	Start Date:	End Date:	Outcome:

For Psoriatic Arthritis Requests:

3. Does the patient have moderate-to-severe psoriatic arthritis? Yes No

4. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of ONE conventional systemic DMARD therapy (i.e., azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate, or sulfasalazine)? Yes No

Drug Name/Strength:	Start Date:	End Date:	Outcome:

For Psoriasis Requests:

5. Does the patient have moderate-to-severe psoriasis? Yes No

6. Which of the following applies to the patient?
 >10% BSA involvement Intractable pruritus Other: _____
 Psoriasis occurring on select locations (i.e., hands, feet, scalp, face, or genitals)

7. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of ONE conventional therapy (i.e., acitretin, anthralin, calcipotriene, calcitriol, coal tar products, cyclosporine, methotrexate, pimecrolimus, PUVA [phototherapy], tacrolimus, tazarotene, topical corticosteroids)? Yes No

Drug Name/Strength:	Start Date:	End Date:	Outcome:

For Ulcerative Colitis Requests:

8. Does the patient have moderate-to-severe ulcerative colitis? Yes No

9. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of ONE conventional therapy (i.e., 6-mercaptopurine, azathioprine, balsalazide, corticosteroids, cyclosporine, mesalamine, sulfasalazine)? Yes No

Drug Name/Strength:	Start Date:	End Date:	Outcome:

Please continue to the next page.

Patient Name:	DOB:
---------------	------

For Crohn's Disease Requests:			
10. Does the patient have moderate-to-severe Crohn's disease? <input type="checkbox"/> Yes <input type="checkbox"/> No			
11. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of ONE conventional therapy (i.e., 6-mercaptopurine, azathioprine, balsalazide, corticosteroids, cyclosporine, mesalamine, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No			
Drug Name/Strength:	Start Date:	End Date:	Outcome:

For Uveitis Requests:			
12. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of ONE conventional therapy (i.e., corticosteroids, methotrexate, azathioprine, mycophenolate mofetil)? <input type="checkbox"/> Yes <input type="checkbox"/> No			
Drug Name/Strength:	Start Date:	End Date:	Outcome:

For Ankylosing Spondylitis Requests:			
13. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of TWO conventional therapy (i.e., NSAIDs – ibuprofen, naproxen, etodolac, celecoxib)? <input type="checkbox"/> Yes <input type="checkbox"/> No			
Drug Name/Strength:	Start Date:	End Date:	Outcome:

For Hidradenitis Suppurativa Requests:			
14. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of ONE conventional therapy (i.e., systemic antibiotic therapy [clindamycin, minocycline, doxycycline, rifampin], metformin, oral contraceptives, spironolactone)? <input type="checkbox"/> Yes <input type="checkbox"/> No			
Drug Name/Strength:	Start Date:	End Date:	Outcome:

Please continue to the next page.

Patient Name:	DOB:
---------------	------

For Atopic Dermatitis Requests:

15. Does the patient have moderate-to-severe atopic dermatitis? Yes No

16. Which of the following applies to the patient?
 $\geq 10\%$ BSA ≥ 7 EASI score ≥ 29 SCORAD score ≥ 3 IGA score Other: _____

17. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 4 weeks of TWO topical steroids OR the affected areas are difficult to treat with prolonged topical corticosteroid exposure (i.e., hands, feet, face, scalp, genitals)? Yes No

18. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 6 weeks of ONE topical calcineurin inhibitor (i.e., pimecrolimus, tacrolimus)? Yes No

19. Has the patient had an inadequate clinical response, intolerance, or contraindication to at least 3 months of ONE conventional systemic therapy? Yes No

Drug Name/Strength:	Start Date:	End Date:	Outcome:

For Renewal Requests:

20. Has the patient's condition improved or stabilized with therapy (i.e., reduction in inflammation/joints affected, affected body surface area, symptom reduction, or endoscopic improvement)? Please provide documentation. Yes No

21. Is the requested agent being used in combination with any other biologic DMARD or targeted synthetic DMARD? Yes No

22. Will the patient receive any live vaccines while on therapy? Yes No

23. Does the patient have any FDA contraindications to the requested agent? Yes No

Prescriber Signature: _____ Date: _____

Authorized Agent's Name: _____

Please fax this request to 602-585-0588 or our secure email at care@disclosedrx.com
Mail Requests to: DisclosedRx Clinical Team
PO Box 701 Washington, IN 47501

Additional Comments/Notes: